News | November 10, 2021
India Pharmaceutical Market grows 5% in October 2021
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Acute therapies continue to report strong growth compared to chronic ones.
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
The BiCNU brand and generic market had U.S. sales of approximately US $ 19.4 million MAT for the most recent twelve months ending in August 2021, according to IQVIA Health
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
The company plans to launch its exclusive e-pharmacy and telemedicine services in India by December 2021
Three new molecular diagnostic test panels for influenza and other common respiratory illnesses can be run together or alone using one patient sample
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
Subscribe To Our Newsletter & Stay Updated
